| Literature DB >> 34943740 |
Daniel Ankrah1, Helena Owusu1, Asiwome Aggor1, Anthony Osei1, Agneta Ampomah1, Mark Harrison1, Frempomaa Nelson1, Grace Owusu Aboagye1, Priscilla Ekpale1, Jennifer Laryea1, Julia Selby1, Serwaa Amoah1, Linda Lartey1, Okaikor Addison1, Elizabeth Bruce1, Joyce Mahungu2, Mariyam Mirfenderesky2.
Abstract
The first comprehensive point prevalence survey at the Korle Bu Teaching Hospital (KBTH) was performed as part of the 2019 Global Point Prevalence Survey (Global-PPS) on antimicrobials. The aim was to establish a PPS baseline for the whole hospital and to identify required stewardship interventions. The PPS was conducted over three days in June 2019 using the GLOBAL-PPS standardized method for surveillance of antimicrobial utilization in hospitals to evaluate antimicrobial prescribing. In all, 988 patients were admitted to 69 wards. Overall antimicrobial prevalence was 53.3%. More community-acquired infections (CAI) were treated empirically compared to health-care associated infections (94.0% vs. 86.1% respectively, p = 0.002). Main indications for prescribing antimicrobials were pneumonia (18.4%), skin and soft tissue infections (11.4%) and sepsis (11.1%). Among antimicrobials, systemic antibiotics accounted for 83.5%, of which amoxicillin with beta-lactam inhibitor (17.5%), metronidazole (11.8%) and ceftriaxone (11.5%) dominated. Guideline compliance was 89.0%. Stop/review dates were completed in 33.4% and documented reason was recorded in 53.0% of all prescriptions. If the findings in this PPS can be addressed antimicrobial stewardship at the KBTH stands to improve significantly.Entities:
Keywords: CwPAMS; Ghana; Korle Bu Teaching Hospital; antimicrobial stewardship; point prevalence survey
Year: 2021 PMID: 34943740 PMCID: PMC8698913 DOI: 10.3390/antibiotics10121528
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Antimicrobial prevalence by ward type.
| Ward | % Treated (Number Treated) |
|---|---|
| General or mixed Adult ICU | 100.0 (7) |
| General or mixed Adult MW | 53.6 (246) |
| General or mixed Adult SW | 50.0 (162) |
| Haematology-Oncology PMW | 47.6 (10) |
| Neonatal Intensive Care Unit | 47.7 (41) |
| Paediatric MW | 76.3 (45) |
| Paediatric SW | 50.0 (16) |
| Antimicrobial prevalence | 53.3 (527) |
Abbreviations: ICU: intensive care unit, MW: medical ward, SW: surgical ward, PMW: paediatric medical ward).
Demographics of treated patients.
| Patients | Total 527 | ||||
|---|---|---|---|---|---|
| Adults ≥ 18 years | 379 | (72%) | |||
| Female | Male | Unknown | |||
| ≥60 years | 210 | 104 | 1 | 315 | (83%) |
| >60 years | 25 | 39 | 64 | (17%) | |
| Median age in yrs (iqr *) | 34 (16) | 45 (29) | |||
| Children < 18 years | 148 | (28%) | |||
| Female | Male | Unknown | |||
| <18 years | 18 | 32 | 50 | (34%) | |
| <5 years | 8 | 7 | 15 | (10%) | |
| <24 months | 41 | 41 | 1 | 83 | (56%) |
| Median age in years (iqr) | 0.3 (7) | 1.5 (8) | |||
* interquartile range.
The proportion of antimicrobials for empirical versus targeted treatment per therapeutic use (CAI or HAI).
| Empirical | Targeted | Total | ||||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| CAI | 374 | 94.0 | 24 | 6.0 | 398 | 73.4 |
| HAI | 124 | 86.1 | 20 | 13.9 | 144 | 26.6 |
| 498 | 44 | 542 | ||||
Abbreviations: CAI: community-acquired infection, HAI: healthcare-associated infection.
Various characteristics of the PPS.
| Characteristic | Number | (%) |
|---|---|---|
| Ten commonest diagnoses treated with antimicrobials | ||
| Pneumonia | 58 | 18.4 |
| Skin and soft tissue | 36 | 11.4 |
| Sepsis | 35 | 11.1 |
| Upper respiratory tract infection | 25 | 7.9 |
| Malaria | 24 | 7.6 |
| Infection of central nervous system | 22 | 7.0 |
| Obstetrics/gynaecology infection | 22 | 7.0 |
| Bone and joint infection | 15 | 4.8 |
| Gastro-intestinal infection | 14 | 4.4 |
| Intra-abdominal sepsis | 10 | 3.2 |
| Treatment according to biomarkers ( | ||
| No | 502 | 95.3 |
| Yes | 25 | 4.7 |
| Antibiotic quality indicators by department | ||
| Medical | ||
| Reason in notes | 235 | 76.1 |
| Guidelines missing | 79 | 25.6 |
| Guideline compliant | 122 | 85.9 |
| Stop/review date | 119 | 38.5 |
| Surgical | ||
| Reason in notes | 183 | 44.3 |
| Guidelines missing | 127 | 30.8 |
| Guideline compliant | 135 | 83.3 |
| Stop/review date | 206 | 49.9 |
| Intensive care unit | ||
| Reason in notes | 35 | 41.2 |
| Guidelines missing | 11 | 12.9 |
| Guideline compliant | 38 | 92.7 |
| Stop/review date | 10 | 11.8 |
| Patients with isolated multi-drug resistant pathogen | ||
| Third generation cephalosporin resistant (TGCR) | 2 | 4.4 |
| Carbapenem-resistant enterobacteriaceae | 2 | 4.4 |
| Carbapenem-resistant non fermentor Gram-negative bacilli | 2 | 4.4 |
| ESBL-producing Enterobacteriaceae | 7 | 15.6 |
| ESBL-producing Enterobacteriaceae-TGCR | 1 | 2.2 |
| No MDR recorded | 19 | 42.2 |
| Targeted treatment against other MDR organisms | 10 | 22.2 |
| Vancomycin-resistant enterobacteriaceae (VRE) | 2 | 4.4 |
Total systemic antimicrobials prescribed by class (WHO ATC classification, 2020).
| ATC Code | Total Systemic Antimicrobials | No (%) | |
|---|---|---|---|
| J01 | Antibacterials for systemic use | 807 | 83.5% |
| P01AB | Nitroimidazole derivatives | 83 | 8.6% |
| P01B | Antimalarials | 29 | 3.0% |
| P01B | 28 | ||
| P01BB | 1 | ||
| J02 | Antimycotics for systemic use | 10 | 1.0% |
| J02AC | |||
| J04 | Antimycobacterials | 10 | 1.0% |
| J04AM | |||
| J05 | Antivirals for systemic use | 20 | 2.1% |
| J05AR | 9 | ||
| J05AF | 6 | ||
| J05AG | 4 | ||
| J05AB | 1 | ||
| A07AA | Intestinal Anti-infectives | 7 | 0.7% |
| D01 | Antifungals for dermatological use | 1 | 0.1% |
| D01BA | |||
| 967 | 100% | ||
P01B: artemisinin and derivatives including combinations, P01BB: biguanides, J02AC: triazole derivatives, J04AM: combinations of drugs for treatment of tuberculosis, J05AR: antivirals for treatment of HIV infections, combinations, J05AF: nucleoside and nucleotide reverse transcriptase inhibitors, J05AG: non-nucleoside reverse transcriptase inhibitors, J05AB: nucleosides and nucleotides excl. reverse transcriptase inhibitors.
Antibacterials for Systemic Use (Therapeutic and Prophylactic).
| Therapeutic Prescription | No |
|---|---|
| Penicillins with beta-lactamase inhibitor | 141 |
| 3rd gen cephalosporins | 113 |
| 2nd gen cephalosporins | 86 |
| Beta-lactamase resistant penicillins | 67 |
| Beta-lactamase sensitive penicillins | 12 |
| Penicillins with extended spectrum | 8 |
| Imidazole derivatives | 95 |
| Fluoroquinolones | 86 |
| Aminoglycosides | 66 |
| Lincosamides | 62 |
| Macrolides | 28 |
| Carbapenems | 19 |
| Co-trimoxazole | 17 |
| Tetracyclines | 3 |
| Glycopeptide antibacterials | 2 |
| Combinations of antimicrobials | 1 |
| Nitrofuran derivatives | 1 |
| 807 |
Figure 1Proportional antibiotic use (J01) by class on wards. Abbreviations: NICU: neonatal intensive care unit, HO-PMW: haematology–oncology–paediatric medical ward, PMW: paediatric medical ward, PSW: paediatric surgical ward, ICU: intensive care unit, AMW: adult medical ward, ASW: adult surgical ward.
Figure 2Top 6 indications disaggregated by antibiotic class. Abbreviations: Pneu: pneumonia or lower respiratory tract infection, SST: skin and soft tissue, OBGY: obstetric/gynaecological infections, Pye: upper urinary tract infection, CNS: infection of central nervous system.